Boehringer, Zealand reframe diabetes pact

Share this article:

Boehringer Ingeleim and Zealand Pharma are still diabetes partners but have redefined the relationship they began in 2011.

The companies said in a joint statement that they will continue to collaborate on novel glucagon/GLP-1 dual agonists for diabetes or obesity, but ZP2929 is no longer the keystone compound.

Instead, Zealand gets all rights to ZP2929, and another agent will be swapped in. The companies said the original financial collaboration arrangements are staying put.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA lifts OncoMed partial hold

The FDA froze the clinical trial of anti-Fzd7 vantictumab in July over concern about "bone-related adverse events."

Research links estrogen and binge eating

Baylor College of Medicine researchers have found that an estrogen replacement suppressed binge-eating behavior among lab mice.

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.